The arrival of biosimilar medicinal products on the market has given rise over the past few years to numerous questions, especially concerning their safety. Although generics have now acquired legitimacy, biosimilars don't yet benefit from full confidence. However, one shouldn't compare that which isn't comparable; the generics of chemical medicines have nothing to do with the biosimilars of biotechnology medicines. Specifically, biosimilars of erythropoietin seem to be viewed with a certain fear due to the secondary effects that occurred with the reference product Eprex®. The aim of this paper is to show that the regulatory framework implemented at the European level around these products allows us to be confident as to their efficacy and their safety.
Romayne Stephens citing Christian Schneider (acting divisional head, Paul Ehrlich institute, Langen, Germany; chairman, Biosimilar Medicinal Products Working Party CHMP) ‘EU takes lead in shaping future of biosimilars’, Pharmacy extra: EGA symposium number 39, July/August 2008, Hospital Pharmacy Europe.
3.
Romayne Stephens, citing Arnold Vulto (Hospital pharmacist/pharmacologist, Erasmus University Medical Center, Rotterdam, Netherlands) ‘EU takes lead in shaping future of biosimilars’, Pharmacy extra: EGA symposium, number 39, July/August 2008 Hospital Pharmacy Europe.
KnightJ. F.Service Medical Advisor Benefit Risk Management, Johnson & Johnson, Presentation: Presentation: ‘Immunogenicity of biopharmaceutical’. Hong Kong, 23 July 2008, available at www.pharmacy.cuhk.edu.hk/news/4_workshop_2.php, accessed 29 October 2008.
See EPAR of the different authorized EPO, available at www.emea.europa.eu, accessed 30 October 2008.
9.
Council Regulation (EEC). No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products OJ L 182, 2.7.1992, p. 1–5, available at http://europa.eu/index_fr.htm.
10.
Furthermore, SPCs based on national provisions were granted before Community Regulation no 1768/92 entering into force, and these SPCs grant variable protections depending on the country (maximum protection of 7 years in France).
11.
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use OJ L 136, 30.4.2004, p. 34–57, available at http://europa.eu/index_fr.htm.
12.
Article 10 of Directive 2001/83/CE, modified by Directive 2004/27/CE.
13.
Article 14.11 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004, OJ L 324, 10.12.2007, p. 121–137, available at http://europa.eu/index_fr.htm.
14.
Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, OJ L 159, 27.6.2003, p. 46–94, available at http://europa.eu/index_fr.htm.
15.
International Committee for Harmonization (ICH). Q5E, Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, 13 November 2003, available at http://www.fda.gov/cder/guidance/6003dft.pdf, accessed 29 October 2008.
16.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues; EMEA/CHMP/BWP/49348/2005, 22 February 2006; available at http://www.emea.europa.eu/pdfs/human/biosimilar/4934805en.pdf, accessed 29 October 2008.
17.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues EMEA/CHMP/BMWP/42832/2005, 22 February 2006, available at http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf, accessed 29 October 2008.
18.
“Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. Guidance on biosimilar medicinal products containing recombinant erythropoietins.” EMEA/CHMP/BMWP/94526/2005 Corr., available at: http://www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf, accessed 29 October 2008.
BouchetBrunetCanaud and all. Consensus conference, (2007) Position statement on use of biosimilars of the société de néphrologie, société francophone de dialyse and la société de néphrologie pédiatrique. Portuguese Journal of Nephrology and Hypertension21(3): 209–210, available at http://www.spnefro.pt/RPNH/PDFs/n3_2007/artigo_06.pdf, accessed 29 October 2008.
21.
BouchetBrunetCanaudDeray and all. “Recommandations d'utilisation des biosimilaires de l'Erythropoiétine (EPO) – Propositions de la Société de Néphrologie, de la Société Francophone de Dialyse et de la Société de Néphrologie Pédiatrique,” 2008, available at http://www.soc-nephrologie.org/esociete/groupes/biosimilaires/index.htm, accessed 29 October 2008.
22.
MellstedtH.NiederwieserD.LudwigH. (2008) The challenge of biosimilars. Annals of Oncology19: 411–419, doi:10.1093/annonc/mdm345, 14 September 2007, available at http://annonc.oxfordjournals.org/cgi/content/abstract/mdm345v1, accessed 29 October 2008.
23.
“Concept paper on the revision of the guidance on similar biological products containing recombinant ertythropoietins,” EMEA/CHMP/BMWP/170734/2008, 24 July 2008, available at http://www.emea.europa.eu/pdfs/human/biosimilar/17073408en.pdf, accessed 29 October 2008.
24.
EhmannF., MD, PhD, EMEA, UK, presentation: “Biosimilar in the European Union – Experience gained and Perspectives,” Biosimilars 2008 Conference Washington DC September 2008, available at http://www.biosimilarstoday.com/2008/Ehmann.pdf, accessed 29 October 2008.
25.
Le CotonnecJ.Y.GravelP.Du concept de biosimilaire à l'AMM. Medecine Clinique, Endocrinologie & diabéte, supplement, October 2007, pp. 15–17.
SinghA. K.MB, FRCP, MRA, Brigham and Women's Hospital Harvard Medical School. Presentation: “Quality and safety of Epoetin biosimilars from developing countries,” 23 July 2008, available at www.pharmacy.cuhk.edu.hk/news/4_workshop_2.php, accessed 29 October 2008.
28.
RossignolN. 6th EGA symposium on biosimilar medicines 2008, reported by Suzette Kox, Senior Director Scientific Affairs European Generic medicines Association, presentation: “EGA Biogenerics and Legislative Issues,” GPhA's 2008 Annual Policy Conference, Washington DC - 17–19 September 2008, available at http://www.egagenerics.com/bio-articles.htm, accessed 29 October 2008.
29.
LocatelliF.RogerS. (2006) Comparative testing and pharmacovigilance of biosimilars. Nephrology Dialysis Transplantation21(Suppl 5): v13–v16, doi:10.1093/ndt/gfl475, available at http://ndt.oxfordjournals.org/cgi/content/full/21/suppl_5/v13, accessed 29 October 2008.
“EGA position following published consensus report on WHO informal consultation with regulators on INN policy for biosimilar medicinal products”, April 2007, available at http://www.egagenerics.com/bio-positions.htm, accessed 30 October 2008.
Volume 9A of The Rules Governing Medicinal Products in the European Union – Guidelines on Pharmacovigilance for Medicinal Products for Human Use – Final September 2008, particularly Chapter I.4 “Requirements for Expedited Reporting of Individual Case Safety Reports,” and Chapter II.1 “Undertaking of Pharmacovigilance Activities by Competent Authorities in the Member States”, available at http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol9_en.htm, accessed 30 October 2008.
PetracekJ. based on the source EudraVigilance Data Warehouse, EMEA/EGA symposium, London, March 2008.
39.
LamarqueV.MerleL. and members of the round table no 7, XXIIIes national meeting of clinical pharmacovigilance. Round table no 7: “Génériques, biosimilaires et modalités de substituabilité: Propositions de méthodes pour évaluer l'équivalence, la traçabilité et le relevé de pharmacovigilance,” available at http://www.ateliersdegiens.org/upload/Giens2007TR7.pdf, accessed 30 October 2008.
40.
GallezRapport: Cf. report in the name of the Commission of Cultural, Family and Social Affairs on the diverse bill on the adapting Community law in the field of medical products, 6 July 2006, available at http://www.assemblee-nationale.fr/12/rapports/r3238.asp, accessed 30 October 2008.
41.
EGA position paper on naming of biopharmaceuticals: A contribution to WHO“Review of International Nonproprietary Names (INN) for Biological and Biotechnological Substances,” 31 October 2006, available on http://www.egagenerics.com/bio-positions.htm, accessed 30 October 2008.
CovicA.Biosimilars and biopharmaceuticals: What the nephrologists need to know – A position paper by the ERA-EDTA Council. October 2008, available at http://ndt.oxfordjournals.org/cgi/content/full/gfn519v2, accessed 30 October 2008.
KotlikoffL. J.Stimulating innovation in the biologics industry: A balanced approach to marketing Exclusivity. September 2008, available at http://people.bu.edu/kotlikoff/, accessed 30 October 2008.
